nach oben

Osteoporosis International

Erschienen in:

01.06.2007 | Case Report

Hepatotoxicity induced by alendronate therapy

verfasst von: B. Yanık, C. Turkay, H. Atalar

Erschienen in: Osteoporosis International | Ausgabe 6/2007

Einloggen, um Zugang zu erhalten

Abstract

Here we describe a 47-year-old postmenopausal woman who had been taking alendronate 70 mg/week for osteoporosis. After two months of alendronate therapy, she developed hepatotoxicity, and no other etiological factors for this besides the alendronate were apparent. After the alendronate therapy was discontinued, the patient’s hepatic enzyme levels slowly returned to normal. Hepatotoxicity due to alendronate therapy is a rare but possible adverse effect.

Peter C, Rodan GA (1999) Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3–8PubMed

Felsenberg D, Alenfeld F, Bock O, Hammermeister C, Gowan W (1998) Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. FOSIT-Study-Group. Fosamax International Trial. Maturitas 31:35–44PubMedCrossRef

Watts N, Freedholm D, Daifotis A (1999) Alendronate: from the laboratory to the patient: the clinical tolerability profile of alendronate. Int J Clin Pract 101:51–61

Eisman JA, Rizzoli R, Roman-Ivorra J, Lipschitz S, Verbruggen N, Gaines KA, Melton ME (2004) Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 20:699–705PubMedCrossRef

Greenspan S, Field-Munves E, Tonino R, Smith M, Petruschke R, Wang L, Yates J, de Papp AE, Palmisano J (2002) Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 77:1044–1052PubMed

Pols HA, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRef

Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 10:183–192PubMedCrossRef

Ferrari AP Jr, Domingues SH (1998) Esophageal ulcer and alendronate. Sao Paulo Med J 116:1882–1884CrossRef

Nase JB, Suzuki JB (2006) Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 137:1115–1119PubMed

10.

Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K (2006) Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 12:48–53PubMed

11.

Coleman CI, Perkerson KA, Lewis A (2004) Alendronate-induced auditory hallucinations and visual disturbances. Pharmacotherapy 24:799–802PubMedCrossRef

12.

Mayoral W, Lewis JH, Zimmerman H (1999) Drug-induced liver disease. Curr Opin Gastroenterol 15:208–216PubMedCrossRef

13.

Lieverse RJ (1998) Hepatitis after alendronate. Neth J Med 53:271–272PubMedCrossRef

14.

Halabe A, Lifschitz BM, Azuri J (2000) Liver damage due to alendronate. N Engl J Med 343:365–366PubMedCrossRef

15.

de La Serna Higuera C, Perez Villoria A, Rodriguez Gomez S, Martinez Moreno J, Betancourt Gonzalez A, Martin Arribas M (2001) Alendronate-induced hepatocellular lesion Gastroenterol Hepatol 24:244–246

16.

Carrere C, Duval JL, Godard B, De Jaureguiberry JP, Ciribilli JM (2002) Severe acute hepatitis induced by alendronate. Gastroenterol Clin Biol 26:179–180PubMed

Titel: Hepatotoxicity induced by alendronate therapy
verfasst von: B. Yanık
C. Turkay
H. Atalar
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Osteoporosis International / Ausgabe 6/2007
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0323-2

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

25.04.2024 | Hypertonie | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hepatotoxicity induced by alendronate therapy

Abstract

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2007

Preventing fractures among older people living in institutional care: a pragmatic randomised double blind placebo controlled trial of vitamin D supplementation

Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study

Non-compliance: the Achilles' heel of anti-fracture efficacy

Bone cross-sectional geometry in adolescents and young women with anorexia nervosa: a hip structural analysis study

Time trends of mortality after first hip fractures

Fracture risk and antiresorptive medication use in older women in the USA

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Update Orthopädie und Unfallchirurgie